ERBB2 and neoplasm: For the different BluePrint dual subtypes a significant difference in OS was observed (only subtypes with n > 10 analyzed; Fig. 5d; Additional file 2: Table S3) in Kaplan–Meier analysis, where patients with a single-Luminal-type tumor had the best 5-year OS (96.7%, 95% CI 92.2–100; Additional file 2: Table S3) and patients with HER2-Basal subtypes had the worst outcome (5-year OS 63.7%, 95% CI 40.7–99.5; Additional file 2: Table S3).